Belvarafenib in Combination With Cobimetinib in Patients With Locally Advanced or Metastatic NRAS-Mutant Melanoma

This trial is testing a combination of two targeted drugs — belvarafenib (a RAF inhibitor) and cobimetinib (a MEK inhibitor) — in people with advanced or metastatic melanoma (skin cancer that has spread) carrying a specific genetic mutation called NRAS. These drugs work by blocking two proteins in the same cancer growth pathway. **You may be eligible if:** - You are 19 years of age or older - You have been diagnosed with locally advanced or metastatic melanoma confirmed by biopsy - Your tumor carries an NRAS mutation - Your cancer has progressed after standard treatments or no standard treatment exists - You have at least one measurable tumor on imaging - Your general health is adequate (ECOG performance status ≤2) - Your kidney, liver, and blood counts are in acceptable range **You may NOT be eligible if:** - You have previously been treated with RAF, MEK, or ERK inhibitor drugs - You have a history of or current retinal eye disease (particularly conditions that could cause vision problems or retinal vein occlusion) - You have significant heart disease or heart rhythm problems - You had a serious bleeding event (Grade 3 or higher) within the past 4 weeks Talk to your doctor to see if this trial is right for you.